North America Quantitative Structure-Activity Relationship Market to Grow at a CAGR of 4.2% to reach US$ 786.6 million Million from 2020 to 2027

The quantitative structure-activity relationship market in North America is expected to grow from US$ 590.2 million in 2020 to US$ 786.6 million by 2027; it is estimated to grow at a CAGR of 4.2% from 2020 to 2027.

The quantitative structure-activity relationship is a computational modelling method used for revealing relationships between structural properties of chemical compounds and biological activities. The drug discovery and development with potential therapeutic applications is a complicated, expensive, and time-consuming venture, for which various computational methodologies such as QSAR have been adopted to increase the efficiency of drug discovery. From hit identification to lead optimization, techniques such as a ligand or structure-based virtual screening are widely being used by various pharmaceutical companies. With the help of modelling, existing data can be leveraged to gain product safety and effectiveness insights. Owing to the efficiency of computational methods, the FDA and EMA have incorporated drug modelling to achieve efficient drug development. In addition, in-Silico design (computer-aided) is being utilized to expedite and facilitate hit identification, optimize the distribution, absorption, metabolism, and toxicity profile to avoid safety issues. Commonly used in-silico approaches include ligand-based structure-based drug design, drug design, and quantitative structure-activity relationships. As these methods are faster and provide valuable insights into experimental findings and mechanisms of action, various pharmaceutical companies have started adopting these techniques for better outcomes.

The first of the National Institute of Allergy and Infectious Diseases’ (NIAID) Covid-19 research priorities is to improve understanding of the disease and the novel coronavirus that causes it, SARS-CoV-2. This helps with understanding the transmission of the disease, including determining whether it is likely to be seasonally circulating, as well as why Covid-19 so dramatically affects some individuals, while others remain asymptomatic. But better knowledge about the virus and the disease can also support the identification of new drug targets or which existing drugs could help tackle this viral disease. Drugs are essential to stopping more suffering at the hands of Covid-19; at the time of writing, more than 461,000 people have tragically died from the disease in the US. The most critical method for anti-SARS-CoV-2 drug discovery includes the de novo development of new, specific drugs based upon the genomic and biophysical understanding of this virus. For instance, the determination of key SARS-CoV-2 targets may bring about the production of siRNA molecules or inhibitors against specific viral enzymes correlated with viral replication. The intensive vaccines and potential immunity boosting drug development procedures and ramping up of food testing services, which is expected to create a positive impact on the growth of quantitative structure-activity relationship (QSAR) market in the North American region.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the quantitative structure-activity relationships market. The North America quantitative structure-activity relationships market is expected to grow at a good CAGR during the forecast period.

North America Quantitative Structure-Activity Relationship Market Segmentation       

By Application

• Drug Discovery
• Molecular Modelling
• Chemical Screening
• Regulatory and Decision-Making
• Others

By End User

• Pharmaceuticals
• Cosmetics
• Environmental
• Food and Beverage

By Country

• North America

  • US
  • Canada
  • Mexico

Companies Mentioned

• ProtoQSAR SL
• Intertek Group Plc
• Laboratory Corporation of America Holdings
• LATHAM BIOPHARM GROUP
• NSF INTERNATIONAL.
• Creative Biolabs

North America Quantitative Structure-Activity Relationship Report Scope